Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview.

“Part of this registry is to start to enable local physicians to speak to patients with motor impairment,” he said. “There’s a lot of interest so we don’t want it to come in a big bottleneck right before the study we’ll be doing.”

New-York based Synchron is farther along in the process of testing its brain implant than Neuralink. Both companies initially aim to help paralyzed patients type on a computer using devices that interpret brain signals.

Synchron received U.S. authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported.